Bladder Cancer
Home / Bladder Cancer
Bladder Cancer
- Immunotherapy: PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, avelumab) have reshaped the treatment landscape for advanced urothelial carcinoma.
- Antibody-Drug Conjugates (ADCs): Enfortumab vedotin (Padcev®) and sacituzumab govitecan (Trodelvy®) offer targeted cytotoxic delivery to resistant tumors.
- Targeted Therapy: Erdafitinib (Balversa®) targets FGFR2/3 mutations, representing a major advancement in biomarker-guided therapy.
Your Financial Contribution Can Help Us Fund Critical Programs & Initiatives
As a Nonprofit organization, we are deeply committed to raising awareness, providing patient support, and advocating for research for individuals living with various disease states.
Quick Links
Rare Diseases
Contact Us
For general questions about our organization, our mission, or how you can get involved, please email us. We endeavor to respond to all inquiries